<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Federated Mdt Balanced Fund Class R6 Shares — News on 6ix</title>
    <link>https://6ix.com/company/federated-mdt-balanced-fund-class-r6-shares</link>
    <description>Latest news and press releases for Federated Mdt Balanced Fund Class R6 Shares on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/federated-mdt-balanced-fund-class-r6-shares" rel="self" type="application/rss+xml" />
    <item>
      <title>Kering: Monthly statement on the total number of shares and voting rights (April 2026)</title>
      <link>https://6ix.com/company/federated-mdt-balanced-fund-class-r6-shares/news/kering-monthly-statement-on-the-total-number-of-shares-and-voting-rights-april-2026-7</link>
      <guid isPermaLink="true">https://6ix.com/company/federated-mdt-balanced-fund-class-r6-shares/news/kering-monthly-statement-on-the-total-number-of-shares-and-voting-rights-april-2026-7</guid>
      <pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
      <description>Kering - Statement Number of Shares and voting rights - 15.04.2026 KeringSociété anonyme with a share capital of €493,683,112Head office: 40, rue de Sèvres –</description>
    </item>
    <item>
      <title>Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting</title>
      <link>https://6ix.com/company/federated-mdt-balanced-fund-class-r6-shares/news/disc-medicine-announces-oral-presentation-of-data-from-rally-mf-phase-2-trial-of-disc-0974-in-patients-with-myelofibrosis-and-anemia-at-the-american-society-of-clinical-oncology-asco-annual-meeting-14</link>
      <guid isPermaLink="true">https://6ix.com/company/federated-mdt-balanced-fund-class-r6-shares/news/disc-medicine-announces-oral-presentation-of-data-from-rally-mf-phase-2-trial-of-disc-0974-in-patients-with-myelofibrosis-and-anemia-at-the-american-society-of-clinical-oncology-asco-annual-meeting-14</guid>
      <pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
      <description>WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,</description>
    </item>
  </channel>
</rss>